Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer.
Ipsen MB, Sørensen EMG, Thomsen EA, Weiss S, Haldrup J, Dalby A, Palmfeldt J, Bross P, Rasmussen M, Fredsøe J, Klingenberg S, Jochumsen MR, Bouchelouche K, Ulhøi BP, Borre M, Mikkelsen JG, Sørensen KD. Ipsen MB, et al. Among authors: ulhoi bp. Oncogene. 2022 Sep;41(37):4271-4281. doi: 10.1038/s41388-022-02427-2. Epub 2022 Aug 6. Oncogene. 2022. PMID: 35933519
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD, Wild PJ, Mortezavi A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, Ørntoft TF, Dyrskjøt L. Sørensen KD, et al. Among authors: ulhoi bp. Clin Cancer Res. 2009 Feb 15;15(4):1400-10. doi: 10.1158/1078-0432.CCR-08-2268. Clin Cancer Res. 2009. PMID: 19228741 Free article.
Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis.
Abildgaard MO, Borre M, Mortensen MM, Ulhøi BP, Tørring N, Wild P, Kristensen H, Mansilla F, Ottosen PD, Dyrskjøt L, Ørntoft TF, Sørensen KD. Abildgaard MO, et al. Among authors: ulhoi bp. Int J Cancer. 2012 Feb 15;130(4):885-95. doi: 10.1002/ijc.26097. Epub 2011 May 25. Int J Cancer. 2012. PMID: 21445975 Free article.
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmström PU, Hartmann A, Palou J, Alvarez-Múgica M, Zieger K, Borre M, Ørntoft TF, Dyrskjøt L. Fristrup N, et al. Among authors: ulhoi bp. Am J Pathol. 2012 May;180(5):1824-34. doi: 10.1016/j.ajpath.2012.01.023. Epub 2012 Mar 24. Am J Pathol. 2012. PMID: 22449953
Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.
Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhøi BP, Agerbaek M, Hartmann A, Bertz S, Wittlinger M, Fietkau R, Rödel C, Borre M, Jensen JB, Orntoft T, Dyrskjøt L. Laurberg JR, et al. Among authors: ulhoi bp. BJU Int. 2012 Dec;110(11 Pt C):E1228-36. doi: 10.1111/j.1464-410X.2012.11564.x. Epub 2012 Oct 9. BJU Int. 2012. PMID: 23046361
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.
Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Ulhøi BP, Borre M, Ørntoft TF, Dyrskjøt L. Fristrup N, et al. Among authors: ulhoi bp. Am J Pathol. 2013 Feb;182(2):339-49. doi: 10.1016/j.ajpath.2012.10.017. Epub 2012 Nov 28. Am J Pathol. 2013. PMID: 23201130 Free article.
Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.
Sørensen KD, Abildgaard MO, Haldrup C, Ulhøi BP, Kristensen H, Strand S, Parker C, Høyer S, Borre M, Ørntoft TF. Sørensen KD, et al. Among authors: ulhoi bp. Br J Cancer. 2013 Feb 5;108(2):420-8. doi: 10.1038/bjc.2012.549. Epub 2013 Jan 15. Br J Cancer. 2013. PMID: 23322201 Free PMC article.
72 results